cyrilzakka/clinical-trials huggingface dataset:
Trends of Vitreoretinal Surgery in Children

Purpose: We determined the incidence, etiology, and longitudinal trends of vitreoretinal diseases necessitating pars plana vitrectomy (PPV) in the pediatric and adolescent population.

Design: This was a nationwide, population-based cohort study, utilizing data from the Korean National Health Claims database spanning from 2009 to 2020.

Given the retrospective design of the study and the anonymized nature of the data, the requirement for informed consent was waived.

Methods: All pediatric and adolescent patients (under 20 years of age) who underwent PPV across the Korean population were included. The cumulative incidence of PPV was estimated from 2009 to 2020, with 2009 to 2011 as the washout period. The annual trends of PPV incidence, the proportion of each etiology, and comorbidity were estimated based on sex and specific age groups.


Eligibility Criteria:
Inclusion Criteria:

* We included all pediatric and adolescent patients who underwent complete PPV (registered under code S5121) during the study period from January 2009 to December 2020, and who were continuously enrolled in a medical plan, in our estimates.
Altered Structural-functional Connectivity Coupling on Chronic Subcortical Stroke

The current study aims to reveal the SC-FC coupling pattern and its relationship with motor function in post-stroke survivors with motor dysfunction by multimodal MRI.

Stroke is the leading cause of death and disability in China. Recently, many previous studies suggested exploring the functional reorganization of the motor function among post-stroke survivors is urgent to be solved in both clinical work and applied basic research. Investigating the structural connectivity (SC) of the brain could visualize the anatomical connections between different brain regions and exploring the functional connectivity (FC) could reveal the functional activity patterns of the human brain in resting- and task- states. Previous studies suggested that SC-FC coupling analysis may shed light on exploring biological markers for the assessment and treatment of motor deficits in post-stroke survivors. The current study aims to reveal the SC-FC coupling pattern and its relationship with motor function in post-stroke survivors with motor dysfunction by multimodal MRI.

Eligibility Criteria:
Inclusion Criteria:

1. Comply with the diagnostic criteria of "Stroke" in the 2010 "Guidelines for the Prevention and Treatment of Cerebrovascular Diseases in China," and confirmed by head CT or MRI.
2. First onset unilateral subcortical stroke (basal ganglia, thalamus, internal capsule, corona radiata, lateral ventricles, etc.).
3. Age ranged from 30 to 75 years old.
4. Right-handedness before stroke.
5. Greater than three months since stroke onset and Brunnstrom graded as III-VI; 6. The condition and vital signs are stable.

7. Sign the informed consent form.

Exclusion Criteria:

1. Any contraindications for the MRI examination.
2. History of other brain diseases and drug dependency.
3. Unstable conditions or accompanied by malignant and rapidly progressing diseases, such as severe atrial fibrillation.
4. Serious communication barriers, cognitive impairment, or cooperation with difficulties.
Biomarkers in Obese Patients With Knee Osteoarthritis; Weight Maintenance

This is a substudy to a randomized trial investigating the effect of liraglutide on body weight and pain in overweight or obese patients with knee osteoarthritis (NCT02905864). In the parent trial, patients will be subjected to an 8-week diet intervention phase including a low-calorie diet and dietetic counseling, after which they will be randomized to receive either liraglutide 3 mg or liraglutide 3 mg placebo as an add-on to dietetic guidance on re-introducing regular foods and a focus on continued motivation to engage in a healthy lifestyle.

This substudy aims to investigate the impact of, and subsequent change of biomarkers in obese patients with knee osteoarthritis following a randomization to Liraglutide 3 mg or Liraglutide 3 mg placebo treatment between weeks 0-52.


Eligibility Criteria:
Inclusion Criteria:

* Same as parent trial (NCT02905864)

Exclusion Criteria:

* Same as parent trial (NCT02905864)
To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine

A team of researchers from the University of Wisconsin-Madison College of Engineering and Oregon Health \& Science University will test whether clinician training and the use of organizational change strategies are sufficient for disseminating an evidence-based practice (EBP), or if changes to both organizational systems and payer policy results in greater EBP use. Demonstrating the role of payment policy as a driver in the adoption of evidence-based practices could provide a contribution to dissemination and implementation science. This study will employ an intervention that was developed through the Robert Wood Johnson Foundation-funded Advancing Recovery (AR) program. In AR, payer/treatment organization partnerships in 12 states collaborated to remove systemic barriers to the adoption of EBPs such as medication-assisted treatment for substance abuse disorders. The resulting "AR Framework" of payer and organizational change strategies will be tested against its ability to increase the use of the addiction medication buprenorphine as compared to organizational change strategies alone. Buprenorphine is an EBP for treating people addicted to heroin or opioid-based pain medications for non-medical use. Buprenorphine has experienced low adoption rates and is not a standard part of addiction treatment. In Ohio, the location of the study, deaths to due to accidental overdoses of opioids has increased by 304% over the past decade and surpassed auto accidents as the leading cause of accidental deaths in 2006. Ohio was selected for the study because of the public health significance of opioid abuse and because each county in Ohio acts as a stand-alone payer, offering 48 unique eligible payer environments. This trial will develop a deeper understanding of the role payers and treatment organizations play in implementing and disseminating EBPs and will focus on the public health issue of rising opioid abuse.

Buprenorphine (EBP) use data will be collected from November, 2012 to May, 2016 through administrative databases located at the state of Ohio. Participants will be followed for the duration of Buprenorphine use that is an average of 5-7 months. Organizational and Payer data will be collected from January, 2013 to January, 2015. The data from the study will be analyzed and reported during January 2015 to February 2017.

Eligibility Criteria:
Inclusion Criteria:

* Treatment agencies with greater than 75 admissions per year

Exclusion Criteria:

-
Azathioprine in Recurrent Implantation Failure

Azathioprine increase pregnancy rate in patients with recurrent implantation failure


Eligibility Criteria:
Inclusion Criteria:

* age: 20-39
* previous 3 or more failed ivf

Exclusion Criteria:

* intrauterine anomalies
* chronic systemic illness
* chronic pelvic conditions
* sensitivety to azathioprine
Novel Therapy of PAD by Combined Transplantation of BMCs

We analyze the effects of combined intramuscular and intraarterial transplantation of BMCs in patients with PAD. BMCs were transplanted into the ischemic limb.

After 2 and 13 months walking distance and perfusion indices were monitored.


Eligibility Criteria:
Inclusion Criteria:

* severe limb ischemia

Exclusion Criteria:

* infectious disease
* cancer
GORE PROPATEN Vascular Graft vs. Disadvantaged Autologous Vein Graft

The primary patency of the GORE PROPATEN Vascular Graft is equivalent to or better than disadvantaged autologous vein graft in an infragenicular peripheral bypass application at 12 months.

Primary patency is defined as hemodynamic evidence of blood flow through an open graft that has maintained uninterrupted patency and has not previously undergone a revision to restore blood flow. A disadvantaged autologous vein is defined as meeting at least one of the two following criteria: (1) Any autologous vein(s) other than greater saphenous vein deemed usable by the Investigator; (2) Usable ipsilateral or contralateral autologous greater saphenous vein that meets any of the following criteria: (a) Diameter of less than or equal to 3.0 mm; (b) Inadequate length requiring splicing; (c) Poor quality vein that is either sclerotic or phlebitic.

Eligibility Criteria:
Inclusion Criteria:

1. Patient requires below-knee bypass secondary to severe claudication, rest pain or tissue loss due to peripheral arterial occlusive disease.
2. Patient meets the disadvantaged autologous vein criteria described in Section 4.1.
3. Patient has a post-operative life expectancy greater than one year.
4. Patient is at least 21 years of age.
5. Patient is able to comply with all study requirements and be available for follow-up visits at 1, 6, 12, 24 and 36-months post-procedure.
6. Patient is willing and able to provide written, informed consent.

Exclusion Criteria:

1. Patient has had a previous instance of Heparin Induced Thrombocytopenia type 2 (HIT-2) or has known hypersensitivity to heparin.
2. Patient requires an infragenicular bypass for reasons other than peripheral arterial occlusive disease.
3. Patient requires sequential extremity revascularizations or other procedures that require use of additional vascular grafts.
4. Patient is in need of, or is scheduled for, a cardiac surgical procedure or a different vascular surgical procedure within 30 days of study procedure. However, inflow procedures that facilitate the bypass are permitted, as long as they are not performed at the same sitting as the bypass procedure.
5. Patient has been previously randomized for this study.
6. Patient has active infection in the region of graft placement.
Study on 'The Use of Non-contrast Helical Computerized Tomogram in Predicting Treatment Outcomes of Upper Ureteric Stone by Extracorporeal Shock Wave Lithotripsy Using the Sonolith 4000+ Lithotripter'

The purpose of this research is to assess the role of non-contrast helical computerized tomogram in predicting the treatment outcome of upper ureteric stone by extracorporeal shock wave lithotripsy (ESWL).


Eligibility Criteria:
Inclusion Criteria:

* Adult patient (\> 18 years old)
* With solitary upper ureteric stone (defined as ureter above the sacroiliac joint as seen on plain radiography) diagnosed by NCHCT \*(\* can have stones at the other site but the indexed stone is a solitary stone)
* Size 5 to 15 mm in the maximal diameter as measured from plain radiography.
* Planned for primary in-situ ESWL

Exclusion Criteria:

* Patient contraindicated for ESWL - active urosepsis, coagulopathy, pregnant lady etc
* Presence of percutaneous nephrostomy or ureteric stent
* Suspected distal obstruction
Clinical Evaluation of Hydrogel and Silicone Hydrogel Daily Disposable Toric Contact Lenses

This study was to evaluate the patient subjective experiences of two daily disposable toric contact lenses.

This was a participant masked, interventional, prospective, direct refit, bilateral wear study. The purpose of this study was to evaluate the patient subjective experiences of a hydrogel daily disposable toric contact lens when compared to a silicone hydrogel daily disposable toric contact lens after 15 minutes of daily wear each.

Eligibility Criteria:
Inclusion Criteria:

A person was eligible for inclusion in the study if he/she:

* Is at least 18 years of age and has full legal capacity to volunteer.
* Has read and signed an information consent letter.
* Self-reports having a full eye examination in the previous two years.
* Anticipates being able to wear the study lenses for at least 8 hours a day, 5 days a week.
* Is willing and able to follow instructions and maintain the appointment schedule.
* Habitual soft contact lens wearers who currently wear toric contact lenses, or use spectacles for all distances vision correction, for the past 3 months minimum.
* Has a contact lens spherical prescription between plano to - 10.00 (inclusive) best corrected visual acuity of 20/30 or better in either eye.
* Has refractive astigmatism no less than -0.75D and no more than 1.75D in both eyes.
* Can achieve best corrected spectacle distance visual acuity of 20/25 (0.10 logMAR) or better in each eye.
* Can achieve a distance visual acuity of 20/30 (0.18 logMAR) or better in each eye with the study contact lenses.
* Has clear corneas and no active ocular disease.
* Has read, understood, and signed the information consent letter.

Exclusion Criteria:

A person was excluded from the study if he/she:

1. Is participating in any concurrent clinical or research study.
2. Has any known active ocular disease and/or infection that contraindicates contact lens wear.
3. Has a systemic condition that in the opinion of the investigator may affect a study outcome variable.
4. Is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable.
5. Has known sensitivity to the diagnostic sodium fluorescein used in the study.
6. Self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment.
7. Has undergone refractive error surgery or intraocular surgery.
Integrated CBT to Improve Functioning in Veterans With Anxiety and Substance Use

Individual with anxiety and post-traumatic stress disorder often use alcohol in ways that could cause them harm. Treating both mental health concerns and alcohol use at the same time can help reduce difficulties engaging in multiple treatments. The investigators are evaluating how a cognitive behavioral therapy program that helps Veterans with anxiety, posttraumatic stress disorder, and alcohol use at the same time can help improve the participants lives.

Co-occurring hazardous drinking, anxiety disorders, and PTSD are problematic combinations of mental health concerns experienced by deployed Veterans. Veterans who have been deployed are at particular risk for experiencing problems in functioning and reintegration related to mental health disorders and hazardous drinking. Co-occurring anxiety and hazardous drinking heavily impact psychosocial functioning and quality of life. Although cognitive behavior therapy (CBT) can promote psychological recovery through improvements in functioning and quality of life, most CBT protocols do not address co-occurring disorders, leading to inefficient and disjointed treatment. The current research seeks to adapt and test the Unified Protocol (UP) for deployed Veterans with hazardous drinking. The use of combined CBT for both anxiety disorders and hazardous drinking has the potential to more efficiently and effectively improve functioning, reduce symptoms, and promote psychosocial recovery.

Eligibility Criteria:
Inclusion Criteria:

* meeting diagnostic criteria for current anxiety disorder and
* endorsing hazardous alcohol use

Exclusion Criteria:

-need for acute medically-supervised detoxification with exclusionary criteria of

* high-risk suicidality
* psychotic symptoms, or
* cognitive impairment that could interfere with engagement in weekly psychotherapy
Study to Determine the Effects of Nebivolol and Hydrochlorothiazide in African Americans With Hypertension

The main purpose of this study is to evaluate the effects of Nebivolol and Hydrochlorothiazide on blood pressure in African Americans with high blood pressure.

Many blood pressure medications are not effective in African American men and women. The two lower chambers of the heart contract to pump blood to the body. The lower chambers have to relax so they can refill with blood to pump out again. Many patients with high blood pressure have stiffness in the lower chambers which prevents the heart from relaxing so it can properly fill with blood. Some patients with the stiffness in the lower chambers of the heart will develop heart failure.

The study is to test whether or not Nebivolol (Bystolic)and a diuretic Hydrochlorothiazide (HCTZ) will help the heart relax so the heart can properly fill and prevent stiffness of the lower heart chambers.

Eligibility Criteria:
Inclusion Criteria:

* Known Hypertension by history
* Self-described African American

Exclusion Criteria:

* Uncontrolled Diabetes Mellitus (HbA1C\>10)
* Known CAD, Cerebrovascular Disease, PVD or Renovascular Disease
* Liver disease
* Chronic Renal Disease
* Uncontrolled Hypertension (\>199 systolic and/or \>115)
Evaluation of the Efficacy, Safety and Toleration of CT327 Ointment in Patients With Psoriasis Vulgaris

The purpose of this study is to evaluate the effectiveness of 3 dose strengths of CT327 ointment (0.05%, 0.1% and 0.05% w/w) compared to a placebo, when applied twice daily for up to 8 weeks, to the psoriatic plaques of patients with psoriasis vulgaris.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects aged at least 18 years.
* Stable psoriasis vulgaris

Exclusion Criteria:

* Subjects with guttate, erythrodermic, exfoliative or pustular psoriasis.
Below Knee DVT Study

Hospitalized patients are at risk of developing blood clots in the legs (Deep Vein Thrombosis or DVT), which can lead to death if those clots break off and migrate to the lungs. We know that if there is a blood clot in the large leg veins near the hips and in the thighs, treating these patients with high-doses of blood thinners reduces the risk of these deaths.

It is unclear if treating blood clots in the calf with high doses of blood thinners is better than using low doses. In this study, after being diagnosed with a blood clot in the calf, patients will be treated with either low dose or high dose enoxaparin (Lovenox), a blood thinner. We will then see if low dose blood thinner has similar results as high dose blood thinner.


Eligibility Criteria:
Inclusion Criteria:

* Patients over the age of 18 admitted to a trauma or general surgery service will be eligible
* Patients diagnosed with an isolated distal DVT
* Able to obtain informed consent

Exclusion Criteria:

* Patients with a previous diagnosis of hypercoagulability
* Patients on chronic anticoagulation
* Patients with a history of heparin induced thrombocytopenia
* Patients have preexisting contraindications to anticoagulation
* Patients in renal failure requiring adjusted enoxaparin dosing
* Pregnant patients
Sodium Bicarbonate for Acute Peripheral Vertigo

Vertigo is defined as the hallucination of spinning sensation or rotatory movement and is frequently combined with severe nausea and vomiting. In Taiwan, an average of 3.13 cases per 100 persons suffer from acute vertigo attack per year. And 1 in 3 patients with vertigo will have recurrent attack within a year. The sensation of disequilibrium and severe nausea and vomiting urge patients visit emergent department (ED) for help. Therefore, vertigo is one of the most common complaints in ED.

Vertigo can be divided into central type and peripheral type. Central type vertigo included life threatening disease like brainstem hemorrhage or infraction. Although peripheral vertigo is mostly benign, the acute symptoms relief are usually needed. The first line therapy of acute peripheral vertigo is using antihistamine or benzodiazepine with other anti-emetic agents. However, these agents usually have side effects of fatigue and lethargy, which will cause increasing patients' length of stay or elders' risk of falling.

Sodium bicarbonate is widely used in treating hyperkalemia or metabolic acidosis. Its safety and no side effect have also been proved. There were few reports of using sodium for treatment of acute vertigo in Taiwan and Japan. However, there is no strong evidence of comparing this therapy with other medication.

This study hypothesized that there is an equivalence of efficacy between sodium bicarbonate and diphenhydramine for treatment of vertigo. Using sodium can cause less fatigue or lethargy and can decrease ED length of stay. This study aims to perform a double-blinded randomized controlled trial to evaluate the efficacy of sodium bicarbonate for treatment of acute peripheral vertigo.


Eligibility Criteria:
Inclusion Criteria:

* Patients with acute onset vertigo

Exclusion Criteria:

* Pregnancy
* First vertigo episode over 24 hours
* Using any anti-vertigo medicine after onset
* Drug allergy to Sodium bicarbonate or Diphenhydramine
* Diagnosed with central vertigo
* Heart failure NYHA class \>1
* Chronic kidney disease (CKD) stage ≥ 3
A Phase I/II Study of the Safety, Tolerance, and Pharmacokinetics of 9-(2-Phosphonylmethoxyethyl)Adenine ( PMEA; Adefovir ) in Patients With Advanced HIV Disease.

To study the safety, tolerance, pharmacokinetics, and anti-HIV effects of PMEA ( adefovir ) when administered daily by intravenous (IV) and/or subcutaneous (SC) injection in patients with advanced HIV disease.

Patients receive a single IV or SC dose of PMEA daily for 4 weeks. A maximum tolerated dose will be defined for these regimens.

Eligibility Criteria:
Inclusion Criteria

Concurrent Medication:

Allowed:

* Other antiretroviral therapy IF on a stable dose for at least 4 weeks prior to study entry.
* Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole IF on a stable prophylactic regimen for at least 4 weeks prior to study entry.

Patients must have:

* HIV seropositivity.
* Elevated p24 antigen (\> 40 pg/ml).
* Mean CD4 count \<= 100 cells/mm3.
* Life expectancy of at least 3 months.

Prior Medication:

Allowed:

* Other prior antiretroviral therapy.
* Prophylactic therapy with aerosolized pentamidine, oral trimethoprim/sulfamethoxazole (Bactrim, Septra) or dapsone, and fluconazole or ketoconazole.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* Inadequate venous access.
* Active serious infection (other than HIV infection) requiring parenteral antibiotic therapy.
* Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or arrhythmia.
* Psychiatric disturbance or illness that may affect compliance.
* Malignancy other than Kaposi's sarcoma.

Concurrent Medication:

Excluded:

* Investigational agents other than stavudine (d4T).
* Interferon-alpha.
* Ganciclovir.
* Foscarnet.
* Diuretics.
* Amphotericin B.
* Aminoglycoside antibiotics.
* Other nephrotoxic agents.
* Acyclovir at doses \>= 2 g/day.

Prior Medication:

Excluded within 2 weeks prior to study entry:

* Investigational agents other than stavudine (d4T).
* Interferon-alpha.
* Ganciclovir.
* Foscarnet.
* Diuretics.
* Amphotericin B.
* Aminoglycoside antibiotics.
* Other nephrotoxic agents.

Excluded within 4 weeks prior to study entry:

* Systemic therapy for Kaposi's sarcoma. Substance abuse.